- Conditions
- Glioblastoma
- Interventions
- Azeliragon, Temozolomide, Radiation therapy, Surgery or LITT
- Drug · Radiation · Procedure
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 341
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Oral Cavity Cancer
- Interventions
- Pembrolizumab, Patient-Specific Culture Vessel
- Biological · Device
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Epithelial Ovarian Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Interventions
- IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer), Paclitaxel, Carboplatin, Olaparib, Niraparib
- Drug
- Lead sponsor
- Imunon
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 9
- States / cities
- Orlando, Florida • New Orleans, Louisiana • Minneapolis, Minnesota + 6 more
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Breast Inflammatory Carcinoma, Invasive Breast Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
- Interventions
- Carboplatin, Cyclophosphamide, Doxorubicin, Paclitaxel, Panitumumab, Pembrolizumab
- Drug · Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Multiple Myeloma
- Interventions
- KRdD followed by auto-HCT, KRdD only
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 4
- States / cities
- Birmingham, Alabama • Portland, Oregon • Nashville, Tennessee + 1 more
- Conditions
- Rectal Adenocarcinoma
- Interventions
- LY2157299, Capecitabine, Fluorouracil, Tumor specific mesorectal excision
- Drug · Procedure
- Lead sponsor
- Providence Health & Services
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Rectal Cancer, Colorectal Cancer, Rectal Cancer Stage II, Rectal Cancer Stage III
- Interventions
- Prehabilitation Program
- Behavioral
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Acute Lymphoblastic Leukemia, ALL, Childhood, ALL
- Interventions
- Ruxolitinib, Cyclophosphamide, Cytarabine, Mercaptopurine, Vincristine, Pegaspargase, Rituximab, Methotrexate (Intrathecal Administration), Methotrexate (Intravenous Administration), Dexamethasone, Doxorubicin, Thioguanine, Methotrexate Oral Product
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years to 39 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Dallas, Texas
- Conditions
- Neoplasms, Benign, Neoplasms, Malignant
- Interventions
- OxyChip
- Device
- Lead sponsor
- Periannan Kuppusamy
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Crohn Disease, Pediatric Crohns Disease
- Interventions
- Azithromycin, Metronidazole, Standard of Care
- Drug · Other
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 3 Years to 17 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 2
- States / cities
- San Francisco, California • Pittsburgh, Pennsylvania
- Conditions
- Sarcoma of the Extremity, Stage I Soft Tissue Sarcoma of the Trunk and Extremities, Stage IA Soft Tissue Sarcoma of the Trunk and Extremities, Stage IB Soft Tissue Sarcoma of the Trunk and Extremities, Stage II Soft Tissue Sarcoma of the Trunk and Extremities
- Interventions
- Cabozantinib S-malate, Radiation Therapy
- Drug · Radiation
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Recurrent High-grade Glioma, Grade III Astrocytoma, Oligodendroglioma, Oligoastrocytoma, Ependymoma, Grade IV Astrocytoma
- Interventions
- exHSC, Nivolumab, Resection or biopsy
- Biological · Drug · Procedure
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 4 Years to 26 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Renal Cell Carcinoma, Kidney Cancer, Kidney Neoplasm, Renal Carcinoma
- Interventions
- Casdatifan, Zimberelimab
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Durvalumab, Tremelimumab, Thoracic Radiation, lobectomy, Standard of care adjuvant chemotherapy
- Drug · Radiation · Procedure
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Bladder Urothelial Carcinoma
- Interventions
- Stereotactic body radiotherapy, Cemiplimab, Cemiplimab and Fianlimab, Radical cystectomy
- Radiation · Drug · Procedure
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Prostate Cancer
- Interventions
- Enoblituzumab, Standard of Care
- Drug · Other
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 219 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • Baltimore, Maryland • Minneapolis, Minnesota + 2 more
- Conditions
- Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma (PDAC), Resected Pancreatic Adenocarcinoma
- Interventions
- daraxonrasib
- Drug
- Lead sponsor
- Revolution Medicines, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 43
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 33 more
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- Metformin
- Drug
- Lead sponsor
- Rush University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Melanoma
- Interventions
- GM-CSF, Standard of Care
- Drug · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Carcinoma, Non-Small-Cell Lung, Lung Cancer (NSCLC), Lung Neoplasms, Carcinoma, Non-Small-Cell Lung (NSCLC), Lung Disease, Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Non-squamous, Non-small Cell Lung Cancer, Squamous
- Interventions
- PF-08634404, Chemotherapy Regimen 1, Chemotherapy Regimen 2
- Biological · Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 11
- States / cities
- Huntsville, Alabama • Stanford, California • Athens, Georgia + 5 more
- Conditions
- Breast Cancer, Hyperinsulinism, HER2-negative Breast Cancer
- Interventions
- Dapagliflozin 10mg
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Pancreatic Cancer
- Interventions
- Tislelizumab, SX-682
- Drug
- Lead sponsor
- Lei Zheng
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • San Antonio, Texas
- Conditions
- Acute Myeloid Leukemia, Leukemia, Myeloid
- Interventions
- Bioelectrical Impedence Analysis Device, 6 Minute Walk Test, Computed Tomography Scans to Measure Skeletal Muscular Index, Blood Test/Blood Draw, Hand Grip Strength Test
- Device · Other · Diagnostic Test
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 239 participants
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Transplant Rejection
- Interventions
- BIVV020 (SAR445088), Intravenous immunoglobulin (IVIg), Rituximab or biosimilar, Antithymocyte globulin (ATG), Tacrolimus, Mycophenolate, Corticosteroids
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 7
- States / cities
- Los Angeles, California • San Francisco, California • Boston, Massachusetts + 2 more